ABSTRACT
Methylphenidate is the most commonly prescribed psychostimulant medication for attention deficit hyperactivity disorder (ADHD). Its efficacy and tolerability in children and adults have been described in numerous studies. Side effects frequently reported during methylphenidate use include appetite loss, irritability, restlessness, headache, insomnia, abdominal pain, and nausea. Methylphenidate is widely accepted to lower seizure threshold. However, both long-acting and short-acting methylphenidate are generally well tolerated with a similar side effect profile. Here we present a child with ADHD a history of seizure, who developed epileptic seizure following a switch from short-acting methylphenidate to long-acting methylphenidate treatment (Medikinet retard®) discussing with the literature findings.
References
1
Findling RL Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review. Clin Ther. 2008;30:942-57.
2
Rappley MD. Safety issues in the use of methylphenidate: an American perspective. Drug Saf. 1997;17:143-8.
3
Pelham WE, Gnagy EM, Chronis AM, Burrows-MacLean L, Fabiano GA, Onyango AN, Meichenbaum DL, Williams A, Aronoff HR, Steiner RL. A comparison of morning only and morning/late afternoon Adderall to morning only, twice daily, and three times daily methylphenidate in children with attention deficit hyperactivity disorder. Pediatrics. 1999;104:1300-1311.
4
Rapaport MD, Moffit C. Attention-deficit/hyperactivity disorder and methylphenidate: A review of height/weight, cardiovascular and somatic complaint side effects. Cl Psychol Rev. 2002;22:1107-1131.
5
Gucuyener K, Erdemoglu K, Senol S, Sedaroglu A, Soysal S, & Kockar A I. Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities. Journal of Child Neurology. 2003;18:109-112.
6
Coghill D, Seth S. Osmotic, controlled-release methylphenidate for the treatment of ADHD. Expert Opin Pharmacother. 2006;7:2119-38.
7
McGough JJ, McBurnett K, Bukstein O, Wilens TE, Greenhill L, Lerner M, Stein M. Once-daily OROS- Methylphenidate is safe and tolerated in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2006;16:351-356.
8
Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD. Pediatrics. 2001;107:105-120.
9
Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE. A randomized, controlled, effectiveness trial of OROS-Methylphenidate compared to usual care with immediate-release methylphenidate in attention-deficit/hyperactivity disorder. Can J Clin Pharmacol. 2006;13:50-62.
10
Tan M & Appleton R. Attention deficit and hyperactivity disorder, methylphenidate and epilepsy. Archives of Disease in Childhood. 2005;90:57-59.
11
Kanner AM. The use of psychotropic drugs in epilepsy: what every neurologist should know. Semin Neurol. 2005;28:379-88.
12
Klein-Schwartz. Abuse and toxicity of methylphenidate. Curr Opin Pediatr. 2002;14:219-223.
13
Linhares MI, Venancio ET, Lima CN, Feitosa ML, Salviano LH, Souza AG, Alves K, Sousa FC, Woods DJ, Aguiar LM, Fonteles MM. Methylphenidate: Proconvulsant Effect and Action On Acetyl Cholinesterase Activity in Young and Adult Mice. Int J of Pharmacy & Pharmaceutical Sci. 2014;6:7;547.
14
Richer LP, Shevell MI, Rosenblatt BR. Epileptiform Abnormalities in Children With Attention-Deficit-Hyperactivity Disorder. Pediatr Neurol. 2002;26:125-129.
15
Socanski D, Herigstad A, Thomsen PH, Dag A, Larsen TK. Epileptiform abnormalities in children diagnosed with attention deficit/hyperactivity disorder. Epilepsy&Behavior. 2010;19:483-486.
16
Torres AR, Whitney J, Gonzalez-Heydrich J. Attention-deficit/hyperactivity disorder in pediatric patients with epilepsy: review of pharmacological treatment. Epilepsy Behav. 2008;12:217-233.
17
Dunn DW, Kronenberger WG. Childhood epilepsy, attention problems, and ADHD: review and practical considerations. Semin Pediatr Neurol. 2005;12:222-228.
18
CADDRA (Canadian Attention Deficit Hyperactivity Disorder Resource Alliance). Canadian ADHD Practice Guidelines (CAP-Guidelines). Third Edition. Chapter 2:2010; p 2.3.
19
Lawlor B. Clinical Handbook of Psychotropic Drugs. Edited by KZ Bezchibnyk-Butler, JJ Jefferies. 15th edition. 2005.
20
Dunn DW, Austin JK, Harezlak J, Ambrosius WT. ADHD and epilepsy in childhood. Dev Med Child Neurol. 2003;45:50-54.
21
Feldman H, Crumine P, Handen BL, Alvin R, Teodori J. Methylphenidate in children with seizures and attention deficit disorder. Am J Dis Child. 1989;143:1081-1086.
22
Gross-Tsur V, Manor O, Van der Meere J, Joseph A, Shalev RS. Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective? J Pediatr. 1997;130:670-674.
23
Gonzalez-Heydrich J, Whitney J, Waber D, Forbes P, Hsin O, Faraone SV, Dodds A, Rao S, Mrakotsky C, MacMillan C, DeMaso DR, de Moor C, Torres A, Bourgeois B, Biederman J. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy&Behavior. 2010;18:229-237.
24
Gonzalez-Heydrich J, Whitney J, Hsin O. Efficacy of OROSR MPH in Pediatric Epilepsy Plus Attention-Deficit/Hyperactivity Disorder (ADHD) (2006) Paper presented at the meeting of the American Academy of Child and Adolescent Psychiatry; San Diego. 2006.